Roche AG

Roche AG
Roche AG  
Discipline: Medicine/Pharmacology
Pharmacology - Jul 9
New analyses from phase III HAVEN studies support Hemlibra's sustained efficacy, safety and quality of life benefit in people with haemophilia A, with and without factor VIII inhibitors First data of phase IIIb STASEY study reinforces safety profile of Hemlibra seen in pivotal HAVEN 1 clinical trial New analysis of pivotal data suggests addition
Health - Jun 28

Recommendation based on the results of IMpassion130 study in triple-negative breast cancer, an aggressive type of breast cancer with high unmet medical need First positive Phase III cancer immunotherapy study for people with metastatic triple-negative breast cancer Roche today announced that the

Pharmacology - Jun 11

New targeted medicine shown to improve clinical outcomes in people with relapsed or refractory diffuse large B-cell lymphoma compared to a commonly used regimen First-in-class antibody-drug conjugate that specifically targets CD79b, a protein expressed in the majority of B-cells Ninth indication

Pharmacology - Jun 4

Venclexta/Venclyxto plus Gazyva/Gazyvaro showed improvements across multiple efficacy measures compared to Gazyva/Gazyvaro plus chlorambucil, including progression-free survival and deep remissions as determined by minimal residual disease measurement This 12-month, fixed-duration, chemotherapy-f

Pharmacology - Jun 2

Data will be presented at the American Society of Clinical Oncology (ASCO) annual meeting on 2 June 2019 Roche today announced positive additional results of a prespecified exploratory analysis from the Phase III IMpower150 study, which demonstrated that the combination of Tecentriq (atezolizumab

Health - May 16

Phase I/II study of entrectinib, an investigational medicine, showed responses in all paediatric tumour types harbouring neurotrophic tyrosine receptor kinase (NTRK), ROS1 or anaplastic lymphoma kinase (ALK) fusions, including those in the central nervous system Data featured in the ASCO presscas

Health - Jun 18

First tumour-agnostic medicine approved in Japan for adult and paediatric patients with NTRK fusion-positive advanced recurrent solid tumours Approval supported by the data mainly from the pivotal Phase II STARTRK-2 study showing that Rozlytrek shrank tumours in more than half of people with NTRK

Health - Jun 10

Roche and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that they have each received a request for additional information and documentary material (the “Second Request”) from the U.S. Federal Trade Commission (the “FTC”) in connection with the FTC's review of Roche's pending acquisition of Spark.

Pharmacology - Jun 3

Roche data from 17 breast cancer abstracts presented at this year's meeting An overall survival improvement was observed with Tecentriq and nab-paclitaxel in PD-L1-positive metastatic triple-negative breast cancer at the second interim analysis End-of-study results in phase III CLEOPATRA study sh

Health - May 31

Radiologists can now upload their patient records to the same dashboard as patient files from other disciplines First collaboration product enables tumour boards to have a more comprehensive view of each patient in one place Important step in Roche's personalised healthcare strategy to fit treatm

Pharmacology - May 16

Fixed 12-month treatment with Venclexta plus Gazyva significantly reduced risk of disease progression or death by 67% compared to a current standard-of-care Approval for expanded use of Venclexta offers more adults with chronic lymphocytic leukaemia a new treatment option - Roche today announced

website preview


Medicine and Life Sciences